Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the Winter Private Company Showcase, co-hosted by Solebury Trout, Oppenheimer and White & Case on Friday, January 29, 2021 at 11am Eastern Time
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005042/en/
Contacts
Media Contact:
MacDougall
Caroline Rufo, PhD or Kari Watson
(781) 235-3060
crufo@macbiocom.com or kwatson@macbiocom.com
Source: Caraway Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20210125005042/en
